US 11,951,103 B2
Pharmaceutical composition
Hiroki Haniuda, Tokyo (JP); Sachiko Enokizono, Tokyo (JP); Tomoyuki Nakazato, Tokyo (JP); Takuya Tokuda, Tokyo (JP); and Norie Fujiki, Tokyo (JP)
Assigned to KYOWA KIRIN CO., LTD., Tokyo (JP)
Filed by Kyowa Kirin Co., Ltd., Tokyo (JP)
Filed on Nov. 30, 2020, as Appl. No. 17/106,671.
Application 17/106,671 is a continuation of application No. 16/332,033, granted, now 10,894,043, previously published as PCT/JP2017/033161, filed on Sep. 13, 2017.
Claims priority of application No. 2016-178599 (JP), filed on Sep. 13, 2016.
Prior Publication US 2021/0077481 A1, Mar. 18, 2021
Int. Cl. A61K 31/4709 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/14 (2017.01); A61K 47/38 (2006.01); A61K 47/40 (2006.01)
CPC A61K 31/4709 (2013.01) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/14 (2013.01); A61K 47/38 (2013.01); A61K 47/40 (2013.01)] 33 Claims
OG exemplary drawing
 
1. Eye drops comprising a vascular endothelial growth factor (VEGF) receptor inhibitor in a nanoparticle form, wherein the VEGF receptor inhibitor is a compound represented by formula (II):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate of the compound or the salt, and
the VEGF receptor inhibitor has a mean particle size of 400 nm or smaller.